
Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines
PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines The NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for Read More
Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS Read More
US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Read More
An Update on Agendia’s Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions Read More